Please click on any of the headlines below to see the full story.
Antioxidant dry AMD eye drop
An antioxidant eye drop (OT-551, Othera) is being investigated to treat geographic atrophy in dry age-related macular degeneration (AMD). 
Graft rejection therapy enters Phase III
GS-101, Gene Signal's experimental topical ophthalmic solution designed to prevent the rejection of corneal grafts, has entered Phase III trials.
Investigating Collamer's accommodation
STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL).
Novagali withdraws drug marketing application
Novagali Pharma SA has withdrawn the EMEA centralized marketing authorization application for Vekacia (cyclosporin) 0.05% eye drops, which had been intended for the treatment of vernal keratoconjunctivitis (VKC).
European expansion of retinal implant trial
The Phase I three-year feasibility study of the Argus II Retinal Implant for Retinitis Pigmentosa (RP) will be expanded to enrol more patients in Europe, according to an announcement from Second Sight Medical Products, the implant's manufacturer.
For up-to-date news and announcements, please check the latest news section of our website. Alternatively, please sign up for our weekly newsletter.
